Michael P. Zawistoski

Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity

Daniel P. Walker, Michael P. Zawistoski, Molly A. McGlynn et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 86 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Signal Transduction +11

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure–activity relationships and strategies for the elimination of reactive metabolite formation

Daniel P. Walker, F. Christopher Bi, Amit S. Kalgutkar et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 51 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biochemistry +9

Pyrazolinone-piperidine dipeptide growth hormone secretagogues (GHSs)

Philip A. Carpino, Bruce A. Lefker, Steven M. Toler et al. · Bioorganic & Medicinal Chemistry · 2003 · 47 citations

Growth Hormone, Medicine, Physiology +4

Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists

Richard Chesworth, Michael P. Zawistoski, Bruce A. Lefker et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 38 citations · Full text

Molecular Pharmacology, Medicine, Hormonal Receptor +5

Steroidal Glycoside Cholesterol Absorption Inhibitors

Michael P. DeNinno, Peter A. McCarthy, Kimberly C. Duplantier et al. · Journal of Medicinal Chemistry · 1997 · 36 citations